EP2504432B1 - Gefässlinien-zellwachstumsmedien auf hydrogelbasis und verwendungen davon - Google Patents

Gefässlinien-zellwachstumsmedien auf hydrogelbasis und verwendungen davon Download PDF

Info

Publication number
EP2504432B1
EP2504432B1 EP10830680.4A EP10830680A EP2504432B1 EP 2504432 B1 EP2504432 B1 EP 2504432B1 EP 10830680 A EP10830680 A EP 10830680A EP 2504432 B1 EP2504432 B1 EP 2504432B1
Authority
EP
European Patent Office
Prior art keywords
hydrogel
vascular
vol
cells
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10830680.4A
Other languages
English (en)
French (fr)
Other versions
EP2504432A2 (de
EP2504432A4 (de
Inventor
Donny Hanjaya-Putra
Sharon Gerecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2504432A2 publication Critical patent/EP2504432A2/de
Publication of EP2504432A4 publication Critical patent/EP2504432A4/de
Application granted granted Critical
Publication of EP2504432B1 publication Critical patent/EP2504432B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/80—Hyaluronan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10—Cross-linking

Definitions

  • EPCs marrow derived circulating endothelial progenitor cells
  • the growth medium further includes vascular lineage cells.
  • Vascular lineage cells may be, for example, endothelial cells, endothelial progenitor cells, or endothelial colony forming cells.
  • ingredients and additives commonly used in cell culture media may also be included in the medium.
  • Ingredients typically used in cell culture media, particularly for culture media for vascular lineage cells may be included.
  • additional ingredients may include, heparin, endothelial cell growth supplement (ECGS), or fetal calf serum.
  • the oligosaccharide must have at least two reactive groups.
  • a modified oligosaccharide at least two of the saccharide units of the oligosaccharide are modified to have a reactive functional group.
  • the extent of modification may be varied by varying the ratio between the oligosaccharide and the modifying reagent. In some embodiments, more than about 20 % of the saccharide units in the oligosaccharide are modified. In other embodiments, more than about 30%, more than about 40% or more than about 50% of the saccharide units in the oligosaccharide are modified.
  • EPCs cultured on yielding substrate supplemented with high VEGF showed a smaller, but significant, increase in MT1-MMP, MMP-1, and MMP-2 compared to their counterpart cultured in low VEGF concentration ( Figures 2B-2D ).
  • the MMP production decreases as the stiffness of the substrate was reduced ( Figures 2E-2G ).
  • the conditioned media was also analyzed via a modified uronic acid assay as previously reported ( Burdick et al., Biomacromolecules, vol. 6, no. 386-391, 2005 ).
  • SDF-1 and TNF-alpha are known to induce MMP production in ECs (Han, Tuan et al. 2001), in which an optimum MMP secretion was needed to allow vascular branching and network formation ( Sacharidou et al., Blood, vol. 115, no. 25, pp. 5259-5269, 2010 ; Iruela-Arispe et al., Dev. Cell, vol. 16, pp. 222-231, 2009 ; Stratman et al., Blood, vol. 114, no. 2, pp. 237-47, 2009 ).
  • the kinetics of cellular remodeling can be observed at various points throughout vascular morphogenesis by monitoring the uronic acid, a byproduct of the AHA degradation, released in the media.
  • vascular morphogenesis progresses, ECFCs secrete MMP-1,-2, MT1-MMP, Hyal-2, and Hyal-3, the inventive AHA hydrogels are degraded and as a result matrix stiffness decreases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (15)

  1. Gefäßzelllinien-Zellwachstumsmedium, umfassend:
    ein Hydrogel mit einem Elastizitätsmodul von zwischen 10 Pa und 500 Pa, der die Bildung von kapillarartigen Strukturen (Capillary-Like Structures, CLS) mit erweiterten Vakuolen und offenen Lumina aus Gefäßzelllinienzellen gestattet, wobei das Hydrogel eine quervernetzte Mischung aus einem Oligosaccharid und einer quervernetzenden Gruppierung umfasst, wobei das Hydrogel durch ein Enzym spaltbar ist; und
    einen Wachstumsfaktor in einer Menge, die ausreicht, um die Gefäßbildung und Röhrchenbildung zu fördern und die ausreicht, um die MMP-Produktion in Gefäßzelllinienzellen zu stimulieren.
  2. Medium nach Anspruch 1, wobei es sich bei der quervernetzenden Gruppierung um ein Peptid; ein Peptid, das durch eine Matrix-Metalloproteinase spaltbar ist; ein Peptid, das durch mindestens eine aus der Reihe MMP-1, MMP-2 oder MMP-10 spaltbar ist; oder ein Peptid umfassend die Sequenz GCRDGPQGIWGQDRCG handelt.
  3. Medium nach einem von Anspruch 1 oder 2, wobei das Hydrogel weiterhin einen Adhäsionspromoter umfasst, und zwar in einer Menge, die ausreicht, um die Adhäsion der Gefäßzelllinienzelle an das Hydrogel zu fördern und die Vakuolen- und Lumenbildung in Gefäßzelllinienzellen zu fördern.
  4. Medium nach Anspruch 3, wobei es sich bei dem Adhäsionspromoter um ein Peptid, das eine RGD-Sequenz und eine reaktionsfähige funktionelle Gruppe, die fähig ist, den Adhäsionspromoter an das Oligosaccharid zu binden, beinhaltet, handelt.
  5. Medium nach einem der Ansprüche 1-4, wobei das Hydrogel ein Elastizitätsmodul von weniger als 250 Pa aufweist.
  6. Medium nach einem der Ansprüche 1-5, wobei die quervernetzte Mischung weiterhin einen zusätzlichen Bestandteil, ausgewählt aus der Gruppe bestehend aus Gelatine, Collagen, Fibrin und Laminin, umfasst.
  7. Medium nach einem der Ansprüche 1-6, wobei das Oligosaccharid mit einer Acrylgruppe oder einer Thiolgruppe modifiziert ist.
  8. Medium nach einem der Ansprüche 1-7, wobei das Oligosaccharid aus der Gruppe bestehend aus Hyaluronsäure, Dextran, Alginat-Chitosan und acrylierter Hyaluronsäure ausgewählt ist.
  9. Medium nach einem der Ansprüche 1-8, wobei es sich bei dem Wachstumsfaktor um VEGF, TNFα, SDF1-α, bFGF, Angiopoetin-1, PDGF, TGF-β, PIGF oder Kombinationen davon handelt.
  10. Medium nach einem der Ansprüche 1-9, das weiterhin Gefäßzelllinienzellen umfasst, die gegebenenfalls aus der Gruppe bestehend aus Endothelzellen, Endothelvorläuferzellen und ECFC(Endothelial Colony Forming Cells)-Zellen ausgewählt sind.
  11. Verfahren zum Induzieren der Vascularisierung, bei dem man Gefäßzelllinienzellen in einem Gefäßzelllinien-Zellwachstumsmedium nach einem der Ansprüche 1-10 kultiviert.
  12. Verfahren nach Anspruch 11, wobei die Vascularisierung der Gefäßzelllinienzellen innerhalb des Hydrogels oder an der Oberfläche des Hydrogels erfolgt.
  13. Verfahren zur Herstellung eines Gefäßnetzwerks, umfassend Folgendes:
    Herstellen eines Gefäßzelllinienwachstumsmediums nach einem der Ansprüche 3-10 durch
    (a) chemisches Binden des Adhäsionspromoters an das Oligosaccharid;
    (b) Kombinieren des chemisch gebundenen Adhäsionspromoters/Oligosaccharids mit mindestens einem Wachstumsfaktor;
    (c) Zufügen einer quervernetzenden Gruppierung, die fähig ist, ein Hydrogel mit dem Oligosaccharid zu bilden, zu der Kombination; und
    (d) Vernetzen der Kombination unter Bildung des Hydrogels;
    wobei Gefäßzelllinienzellen vor dem Vernetzen, während des Vernetzens oder nach dem Vernetzen zugefügt werden; und anschließendes
    Inkubieren der Gefäßzelllinienzellen unter Bildung eines Gefäßnetzwerks.
  14. Verfahren zum Züchten von Blutgefäßen in vitro durch Inkubieren von Gefäßzelllinienzellen mit einem Medium nach einem der Ansprüche 1-10.
  15. Gefäßzelllinien-Zellwachstumsmedium nach einem der Ansprüche 1-10 zur Verwendung in der Förderung des Gefäßwachstums in einem Individuum durch Inkontaktbringen des Individuums mit dem Medium.
EP10830680.4A 2009-11-10 2010-11-10 Gefässlinien-zellwachstumsmedien auf hydrogelbasis und verwendungen davon Active EP2504432B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982109P 2009-11-10 2009-11-10
PCT/US2010/056268 WO2011060095A2 (en) 2009-11-10 2010-11-10 Hydrogel-based vascular lineage cell growth media and uses thereof

Publications (3)

Publication Number Publication Date
EP2504432A2 EP2504432A2 (de) 2012-10-03
EP2504432A4 EP2504432A4 (de) 2014-07-02
EP2504432B1 true EP2504432B1 (de) 2018-02-14

Family

ID=43992383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10830680.4A Active EP2504432B1 (de) 2009-11-10 2010-11-10 Gefässlinien-zellwachstumsmedien auf hydrogelbasis und verwendungen davon

Country Status (5)

Country Link
US (2) US8900868B2 (de)
EP (1) EP2504432B1 (de)
CA (1) CA2780490C (de)
IL (1) IL219728A (de)
WO (1) WO2011060095A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2746781C (en) 2008-12-17 2017-03-28 The Johns Hopkins University Biocompatible polysaccharide-based hydrogels
CA2780490C (en) 2009-11-10 2021-01-26 The Johns Hopkins University Hydrogel-based vascular lineage cell growth media and uses thereof
WO2012003370A2 (en) 2010-06-30 2012-01-05 The Johns Hopkins University Functional vascularization with biocompatible polysaccharide-based hydrogels
US20150174154A1 (en) * 2011-05-06 2015-06-25 The Johns Hopkins University Skin and hair regeneration using polysaccharide-based hydrogels
US20130060348A1 (en) * 2011-09-01 2013-03-07 Tyco Healthcare Group Lp Hydrogel Coated Magnesium Medical Implants
EP2698636A1 (de) * 2012-08-13 2014-02-19 Fundació Institut d'Investigació Biomèdica de Bellvitge Verfahren und Reagenzien zur Vorbeugung und/oder Behandlung von Transplantatabstoßung
WO2014113573A1 (en) 2013-01-17 2014-07-24 The Regents Of The University Of California Growth factor sequestering and presenting hydrogels
US9670447B2 (en) 2013-01-29 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microfabricated polymeric vessel mimetics
US20160243281A1 (en) * 2013-10-04 2016-08-25 The Regents Of The University Of California Hyaluronic acid and alginate hydrogel composition
US10195313B2 (en) 2014-04-10 2019-02-05 Wisconsin Alumni Research Foundation Method for forming hydrogel arrays using surfaces with differential wettability
EP3439670A4 (de) * 2016-04-08 2019-11-27 The Regents of the University of California Modifizierte hyaluronsäure-hydrogele und proteine zur zeitgesteuerten freisetzung von biologischen wirkstoffen
WO2018187184A1 (en) * 2017-04-04 2018-10-11 The Regents Of The University Of California Injectable therapeutic angiogenic material for brain repair
KR20200028391A (ko) * 2017-06-12 2020-03-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 세포 생착용 패치 이식편 조성물
JP7418363B2 (ja) * 2018-06-21 2024-01-19 イエール ユニバーシティ バイオ人工血管膵臓
WO2020264327A1 (en) * 2019-06-26 2020-12-30 Gemstone Biotherapeutics Llc Extracellular matrices, uses thereof, and methods of making extracellular matrices

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US20020081729A1 (en) * 1998-03-27 2002-06-27 Martin C. Peters Controlled release of tissue culture supplements
ATE297440T1 (de) 1998-08-31 2005-06-15 Cornell Res Foundation Inc Dextran-maleinsäuremonoester und hydrogele daraus
US6716445B2 (en) 1999-04-12 2004-04-06 Cornell Research Foundation, Inc. Hydrogel entrapping therapeutic agent and stent with coating comprising this
AU1249001A (en) * 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
CA2476656C (en) * 2002-02-21 2008-11-25 Encelle, Inc. Immobilized bioactive hydrogel matrices as surface coatings
US7794706B2 (en) 2003-10-14 2010-09-14 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
WO2005074836A1 (en) 2004-01-29 2005-08-18 Brown University Methods for progenitor cell recruitment and isolation
AU2005244848A1 (en) 2004-05-12 2005-12-01 Medivas, Llc Wound healing polymer compositions and methods for use thereof
US20060165667A1 (en) 2004-12-03 2006-07-27 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
CN101677957A (zh) 2007-02-05 2010-03-24 卡比兰生物外科公司 用于递送生物活性试剂的聚合物制剂
US8293510B2 (en) 2007-11-16 2012-10-23 University Of Kansas Method of preparing a hydrogel network encapsulating cells
WO2009134414A2 (en) 2008-04-30 2009-11-05 The Board Of Trustees Of The Leland Stanford Junior University Devices for the treatment of wounds and methods and kits thereof
CA2746781C (en) 2008-12-17 2017-03-28 The Johns Hopkins University Biocompatible polysaccharide-based hydrogels
CA2780490C (en) 2009-11-10 2021-01-26 The Johns Hopkins University Hydrogel-based vascular lineage cell growth media and uses thereof
WO2012003370A2 (en) 2010-06-30 2012-01-05 The Johns Hopkins University Functional vascularization with biocompatible polysaccharide-based hydrogels
US20150174154A1 (en) 2011-05-06 2015-06-25 The Johns Hopkins University Skin and hair regeneration using polysaccharide-based hydrogels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
IL219728A0 (en) 2012-07-31
CA2780490C (en) 2021-01-26
US20150166962A1 (en) 2015-06-18
WO2011060095A2 (en) 2011-05-19
CA2780490A1 (en) 2011-05-19
WO2011060095A3 (en) 2011-11-24
EP2504432A2 (de) 2012-10-03
US20120225814A1 (en) 2012-09-06
IL219728A (en) 2017-11-30
US8900868B2 (en) 2014-12-02
EP2504432A4 (de) 2014-07-02
US9447381B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
EP2504432B1 (de) Gefässlinien-zellwachstumsmedien auf hydrogelbasis und verwendungen davon
Hanjaya-Putra et al. Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix
Xin et al. A collagen scaffold loaded with human umbilical cord-derived mesenchymal stem cells facilitates endometrial regeneration and restores fertility
Luo et al. Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model
Zhang et al. Vascular differentiation of bone marrow stem cells is directed by a tunable three-dimensional matrix
Hanjaya-Putra et al. Spatial control of cell-mediated degradation to regulate vasculogenesis and angiogenesis in hyaluronan hydrogels
Rossi et al. In vivo tissue engineering of functional skeletal muscle by freshly isolated satellite cells embedded in a photopolymerizable hydrogel
Russo et al. Mesenchymal stem cell delivery strategies to promote cardiac regeneration following ischemic injury
Fuoco et al. Matrix scaffolding for stem cell guidance toward skeletal muscle tissue engineering
Teng et al. A chondrogenesis induction system based on a functionalized hyaluronic acid hydrogel sequentially promoting hMSC proliferation, condensation, differentiation, and matrix deposition
US9492484B2 (en) Cardiosphere derived cell population and methods of use
Karunanithi et al. Three dimensional alginate-fucoidan composite hydrogel augments the chondrogenic differentiation of mesenchymal stromal cells
Xu et al. Bioprinting a skin patch with dual-crosslinked gelatin (GelMA) and silk fibroin (SilMA): An approach to accelerating cutaneous wound healing
Levato et al. Role of ECM/peptide coatings on SDF-1α triggered mesenchymal stromal cell migration from microcarriers for cell therapy
TW201902467A (zh) 用於細胞植入的補釘移植物組成物
Papageorgiou et al. Expanded skeletal stem and progenitor cells promote and participate in induced bone regeneration at subcritical BMP-2 dose
Sebinger et al. ECM modulated early kidney development in embryonic organ culture
Gallagher et al. Pre-culture of mesenchymal stem cells within RGD-modified hyaluronic acid hydrogel improves their resilience to ischaemic conditions
Kim et al. Spatially arranged encapsulation of stem cell spheroids within hydrogels for the regulation of spheroid fusion and cell migration
Wang et al. Role of N-cadherin in a niche-mimicking microenvironment for chondrogenesis of mesenchymal stem cells in vitro
Osidak et al. Concentrated collagen hydrogels: A new approach for developing artificial tissues
Du et al. A fibrous hybrid patch couples cell-derived matrix and poly (l-lactide-co-caprolactone) for endothelial cells delivery and skin wound repair
Casanova et al. Chondrogenesis-inductive nanofibrous substrate using both biological fluids and mesenchymal stem cells from an autologous source
Zhang et al. Injectable conductive micro-cryogel as a muscle stem cell carrier improves myogenic proliferation, differentiation and in situ skeletal muscle regeneration
Yao et al. Stem cell extracellular matrix-modified decellularized tendon slices facilitate the migration of bone marrow mesenchymal stem cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120608

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140602

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/12 20060101ALI20140526BHEP

Ipc: C12N 11/06 20060101ALI20140526BHEP

Ipc: C12N 5/071 20100101ALI20140526BHEP

Ipc: C12N 5/02 20060101ALI20140526BHEP

Ipc: A61L 27/38 20060101ALI20140526BHEP

Ipc: C12N 11/04 20060101AFI20140526BHEP

Ipc: A61L 27/54 20060101ALI20140526BHEP

Ipc: C12N 5/07 20100101ALI20140526BHEP

Ipc: A61L 27/52 20060101ALI20140526BHEP

17Q First examination report despatched

Effective date: 20170131

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010048533

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0011040000

Ipc: A61L0027380000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/38 20060101AFI20170620BHEP

Ipc: A61K 35/12 20150101ALI20170620BHEP

Ipc: A61L 27/52 20060101ALI20170620BHEP

Ipc: C12N 5/071 20100101ALI20170620BHEP

Ipc: A61L 27/54 20060101ALI20170620BHEP

Ipc: A61K 35/44 20150101ALI20170620BHEP

INTG Intention to grant announced

Effective date: 20170718

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010048533

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 969466

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180214

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 969466

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180514

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180514

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180515

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010048533

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181110

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180214

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180614

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231127

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231127

Year of fee payment: 14

Ref country code: DE

Payment date: 20231129

Year of fee payment: 14